Perceptive’s China Rx

The life sciences giant is one of at least seven hedge funds that have invested in LianBio, scheduled to go public this week. Here’s why this IPO is different.

Stephen Taub October 25, 2021

Joseph Edelman, CEO of Perceptive Advisors.

(Chris Goodney/Bloomberg)

Perceptive Advisors, a hedge fund firm well known for its public and private investments in life sciences and biopharma companies, is gearing up for the IPO of a company it actually founded.LianBio, a Chinese company focused on developing in-licensed therapies for the Chinese and other

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

develop build:2025-12-18 Login